Vertex Pharmaceuticals/$VRTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Ticker
$VRTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
6,100
ISIN
US92532F1003
Website
VRTX Metrics
BasicAdvanced
$114B
-
-$3.84
0.51
-
Price and volume
Market cap
$114B
Beta
0.51
52-week high
$519.68
52-week low
$377.85
Average daily volume
1.4M
Financial strength
Current ratio
2.646
Quick ratio
2.116
Long term debt to equity
9.997
Total debt to equity
9.997
Interest coverage (TTM)
189.98%
Profitability
EBITDA (TTM)
4,581.5
Gross margin (TTM)
53.09%
Net profit margin (TTM)
-8.91%
Operating margin (TTM)
39.71%
Effective tax rate (TTM)
-229.41%
Revenue per employee (TTM)
$1,820,000
Management effectiveness
Return on assets (TTM)
11.77%
Return on equity (TTM)
-5.64%
Valuation
Price to revenue (TTM)
10.289
Price to book
6.91
Price to tangible book (TTM)
7.61
Price to free cash flow (TTM)
-90.786
Free cash flow yield (TTM)
-1.10%
Free cash flow per share (TTM)
-488.40%
Growth
Revenue change (TTM)
8.98%
Earnings per share change (TTM)
-124.93%
3-year revenue growth (CAGR)
11.78%
10-year revenue growth (CAGR)
33.87%
3-year earnings per share growth (CAGR)
-25.99%
10-year earnings per share growth (CAGR)
2.58%
What the Analysts think about VRTX
Analyst ratings (Buy, Hold, Sell) for Vertex Pharmaceuticals stock.
Bulls say / Bears say
Vertex Pharmaceuticals' cystic fibrosis (CF) treatments, particularly Trikafta, continue to show strong demand, with Trikafta sales increasing by 9% to $2.45 billion in Q2 2024, surpassing analysts' expectations. (reuters.com)
The FDA's approval of Journavx (suzetrigine), a novel non-opioid painkiller, marks a significant expansion of Vertex's product portfolio into the pain management market, potentially opening new revenue streams. (reuters.com)
Vertex's gene therapy, Casgevy, developed in collaboration with CRISPR Therapeutics, has received multiple approvals for treating rare blood disorders, with over 65 authorized treatment centers globally and 90 patients beginning cell collection, indicating promising adoption. (reuters.com)
Vertex missed Wall Street estimates for Q1 2025, with Trikafta sales of $2.53 billion falling short of the expected $2.58 billion, leading to a 2.5% drop in shares after the announcement. (reuters.com)
The company's non-opioid pain drug, suzetrigine, failed to outperform a placebo in a mid-stage trial for lower back pain, raising concerns about its efficacy and potential market impact. (bloomberg.com)
Insider selling activity, such as EVP Ourania Tatsis selling 244 shares in February 2025, might signal a lack of confidence among executives regarding the company's short-term prospects. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 23 Jun 2025.
VRTX Financial Performance
Revenues and expenses
VRTX Earnings Performance
Company profitability
VRTX News
AllArticlesVideos
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
Business Wire·4 days ago
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
Business Wire·7 days ago
3 Monster Stocks to Confidently Own for the Next 10 Years
24/7 Wall Street·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vertex Pharmaceuticals stock?
Vertex Pharmaceuticals (VRTX) has a market cap of $114B as of June 27, 2025.
What is the P/E ratio for Vertex Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 0 as of June 27, 2025.
Does Vertex Pharmaceuticals stock pay dividends?
No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Vertex Pharmaceuticals dividend payment date?
Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.